Lower respiratory tract infections following respiratory syncytial virus monoclonal antibody nirsevimab immunization versus placebo: Analysis from a Phase 3 randomized clinical trial (MELODY)

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

Clinical Infectious Diseases

Topics

Medicine

Epidemiology

Immunology

Pathology

Internal Medicine

Show all topics

DOI

10.1093/cid/ciae596

License

CC-BY

Other Formats

PDF